THX Pharma Société Anonyme (FRA:3VG)

Germany · Delayed Price · Currency is EUR

3.135

-0.100 (-3.09%)

At close: Jun 26, 2026

262.01% (1Y)

Market Cap	43.46M +544.4%
Revenue (ttm)	806.05K -64.7%
Net Income	-3.00M
EPS	-0.22
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	3.135
Previous Close	3.235
Day's Range	3.135 - 3.135
52-Week Range	0.776 - 4.310
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 29, 2026

About FRA:3VG

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France. [Read more]

Industry Pharmaceutical Preparations

Founded 2013

Employees 12

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 3VG

Financial Performance

In 2025, FRA:3VG's revenue was 806,045, a decrease of -64.70% compared to the previous year's 2.28 million. Losses were -3.00 million, 70.0% more than in 2024.

Financial Statements